XI’AN LIBANG PHARMACEUTICAL CO.,LTD. founded in 1996 with the location at Xi’an of China, the centre of the northwest pharmaceutical industry, is specialized in research, development, production and distribution of generic Finished Dosage Forms and high-valued APIs. As the first and also largest supplier of generic Propofol in China, LIBANG started its business and subsequently launched a broad portfolio products covering anesthetics, cardiovascular, antineoplastic, clinical nutrition etc. With more than 10 years growth, LIBANG has transformed into an integrated healthcare solution provider, LIBANG HEALTHCARE GROUP, with diversified fields covering APIs, pharmaceutical excipients, prescription drugs, OTC products, biomedicine, medical devices, etc. LIBANG is a technology-driven firm, with more than 8% of the annual sales revenues devoted to R&D, established a unique R&D platform to proactively follows the latest pharmaceutical technology frontier. LIBANG now is one of Top 100 China’s Pharmaceutical Industries and also listed in the Top 20 The Most Potential Chinese Pharmaceuticals that was rated by the IMS Health.
Libang Pharmaceutical owns ten products awarded “China’s Top 100 Quality & Credit”, and now has expanded its product pipeline to anesthesia series, cardiovascular series, enteral nutrition, parenteral nutrition and anti-cancer series, most of them are bestseller in the Chinese market, as well as exported to more than 20 overseas markets.
Libang has built an excellent R&D team, possessing three R&D entities: Lipont Pharmaceutical Inc Canada, Xi’an Libang-Zhaoxin Bio-tech Inc and Xi’an Libang Medi-tech Inc. 8% to 10% of annual sale revenues is devoted to R&D.
Based on the domestic and Canadian R&D centers, Libang also networks with experts from leading research institutes at home and abroad, such as Tsinghua University, Northwestern University,
University of British Columbia, Canada, established close technical cooperation relationship with several research institutions in the United States.